PURPOSE The aim of this study is to investigate the performance and limitations of a real-time transit electronic portal imaging device (EPID) dosimetry system for error detection during dynamic intensity modulated radiation therapy (IMRT) treatment delivery. Sites studied are prostate, head and neck (HN), and rectal cancer treatments. METHODS The system compares measured cumulative transit E...

OBJECTIVE To determine late toxicity and quality of life (QoL) in patients with localized prostate cancer after high-dose intensity-modulated radiotherapy (IMRT). PATIENT AND METHODS This was a prospective study in patients with localized prostate adenocarcinoma who had been treated by IMRT (76 Gy) between February and November 2006. Physicians scored acute and late toxicity using the Common ...

BACKGROUND The purpose of this study was to determine the expected time to prostate specific antigen (PSA) normalization with or without neoadjuvant androgen deprivation (NAAD) therapy after treatment with intensity modulated radiotherapy (IMRT) for patients with clinically localized prostate cancer. METHODS A retrospective cohort research design was used. A total of 133 patients with clinica...

Radiation therapy has come a long way from treatment planning based on orthogonal radiographs with large margins around tumours. Advances in imaging and radiation planning software have led to three-dimensional conformal radiotherapy and, further, to intensity modulated radiotherapy (IMRT). IMRT permits sparing of normal tissues and hence dose-escalation to tumours. IMRT is the current standard...

BACKGROUND The standard clinical protocol of image-guided IMRT for prostate carcinoma introduces isocenter relocation to restore the conformity of the multi-leaf collimator (MLC) segments to the target as seen in the cone-beam CT on the day of treatment. The large interfractional deformations of the clinical target volume (CTV) still require introduction of safety margins which leads to undesir...

Email:[email protected] Prostate cancer is the most commonly diagnosed cancer among males in the United States.1 The treatment of prostate cancer has several options, including external beam radiation therapy. The primary goal of radiation therapy is to control the tumor by delivering a maximum dose to the tumor site, yet minimizing the radiation dose to normal tissues. The development of...

PURPOSE Hypofractionated radiation therapy as primary treatment for prostate cancer is currently being investigated in large phase 3 trials. However, there are few data on postoperative hypofractionation. The Radiation therapy for the Prostate Bed With or Without the Pelvic Lymph Nodes (PRIAMOS 1) trial was initiated as a prospective phase 2 trial to assess treatment safety and toxicity of a hy...

Purpose: To determine whether radical prostatectomy (RP) or intensity modulated radiation therapy (IMRT) to ≥72 Gy, plus hormonal therapy if indicated, results in improved biochemical disease free survival (BDFS) in localized prostate adenocarcinoma. Methods and Materials: Between 1997-2005, a consecutive sample of 556 patients who underwent RP (n=204) or IMRT (n=352) at two referral centers wa...

PURPOSE Proteomic profiling of patients undergoing intensity-modulated radiotherapy (IMRT) for prostate cancer can identify unique biomarkers that reflect acute toxicity in normal tissues. Our objectives were to measure inflammatory cytokine proteins during IMRT and assess the variability of individual proteomic signatures. EXPERIMENTAL DESIGN Forty-two patients with intermediate-risk prostat...

OBJECTIVE To compare tumour control and toxicity outcomes with the use of high-dose intensity-modulated radiation therapy (IMRT) alone or brachytherapy combined with IMRT (combo-RT) for patients with intermediate-risk prostate cancer. PATIENTS AND METHODS Between 1997 and 2010, 870 consecutive patients with intermediate-risk prostate cancer were treated at our institution with either 86.4 Gy ...